Tuesday, 20 Nov 2018

You are here

Severity of Lupus Nephritis is Declining over Time

A retrospective follow-up study of 499 lupus nephritis (LN) patients over three successive eras shows that LN has become less severe in recent years and thus, better long-term survival is possible.

A multicenter, Italian study examined LN patients over a 46-year period, dividing eras into three periods (P): P1 1970–1985, P2 1986–2001 and P3 2002–2016. Predictors of outcomes were assessed by univariate and multivariate proportional hazards Cox regression analyses.

Investigators noted a progressive increase in patient age at the time of diagnosis (p<0.0001) and a longer interval between SLE onset and LN occurrence (p<0.0001).

Over this same 46 year period the frequency of renal insufficiency at the time of LN presentation significantly decreased (p<0.0001) while isolated urinary abnormalities increased (p<0.0001).

Even though no changes in histological class and activity index were observed, the chronicity index significantly decreased from 1970 to 2016 (p=0.023).

Survival without end-stage renal disease (ESRD) was: 

  • P1: 87% at 10 yrs;  80% at 20 yrs
  • P2: 94% at 10 yrs;  90% at 20 yrs
  • P3: 99% at 10 years (20 yr F/U not available) (p=0.0019).

Predictors of ESRD included: male gender, arterial hypertension, no immunosuppressive therapy, increased creatinine, and a renal biopsy high activity and chronicity index.

These data suggest that time and better treatments have improved the renal outcomes of lupus patients who develop LN.

Conclusions Clinical presentation of LN has become less severe in the last years, leading to a better long-term renal survival.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

AURA-LV Trial - Voclosporin Effective in Lupus Nephritis

The AURA-LV trial assessed voclosporin, a calcineurin inhibitor in patients with active lupus nephritis (LN) and found that low-dose voclosporin may be successfully added to mycophenolate mofetil and corticosteroids to controll active LN.

Pilot Data on Rituximab in Henoch-Schonlein Purpura

Management of Henoch-Schonlein purpura (HSP) can be challenging as supportive care and avoidance of corticosteroids are often insufficient options. A new series of case reports and literature review of steroid refractory HSP suggests that rituximab may be effective in reducing hospital admissions, overall steroid use, and is capable of inducing remission.

Scleroderma Expert Treatment Preferences

Frustration may be the word that best characterizes many scleroderma management plans - owing to a lack of trials, lack of agreement and lack of clear guidance on management.

A panel of concerned experts  on systemic sclerosis (SSc) set out to develop consensus on SSc treatment algorithms.

IgG4-Related Disease: First Draft Criteria Presented at ACR 2018

As Dr. John Stone, MD, MPH recounted in his presentation regarding the new ACR/EULAR Classification Criteria for IgG4-Related Disease (IgG4-RD), only 15 years prior, IgG4-related disease was an unknown entity in the medical community.

Update on Myositis

The ACR/ARHP 2018 national meeting in Chicago presented us with opportunities to learn more about inflammatory myositis. A particularly interesting lecture was HOT topics in myositis. There were a few abstracts on MDA-5 related disease and a few on new or repurposed medications for dermatomyositis which will be covered here.